Abstract:
:Osteoporosis is a systemic bone disease characterized by low bone mass and bone mineral density, and deterioration of the underlying structure of bone tissue. These changes lead to an increase in bone fragility and an increased risk for fracture, which are the clinical consequences of osteoporosis. The classical triad for consideration in osteoporosis is morbidity, mortality and cost. Vertebral fracture is an important source of morbidity in terms of pain and spinal deformity. On the other hand, hip fracture is associated with the worst outcomes and is widely regarded as a life-threatening event in the elderly; it is the source of the bulk of the cost of the disease in contemporary healthcare. The prevention of osteoporosis-associated fracture should include fall prevention, calcium supplementation and lifestyle advice, as well as pharmacological therapy using agents with proven antifracture efficacy. The most commonly used osteoporosis treatments in Europe are the bisphosphonates alendronate, risedronate, ibandronate and zoledronic acid; the selective estrogen receptor modulator (SERM) raloxifene; teriparatide; and strontium ranelate. Recent additions include the biological therapy denosumab and the SERM bazedoxifene. In this review, we explore the antifracture efficacy of these agents with the aim of simplifying treatment decisions. These treatments can be broadly divided according to their mode of action. The antiresorptive agents include the bisphosphonates, the SERMs and denosumab, while the bone-forming agents include parathyroid hormone and teriparatide. Strontium ranelate appears to combine both antiresorptive and anabolic activities. We collated data on vertebral and hip fracture efficacy from the pivotal 3-year phase III trials, all of which had a randomized, double-blind, placebo-controlled design. The relative reductions in risk in the osteoporosis trials range from 30% to 70% for vertebral fracture and 30% to 51% for hip fracture. This translates into 3-year number needed to treat values of between 9 and 21 for vertebral fracture and from 48 upwards for hip fracture. International guidelines agree that agents that have been shown to decrease vertebral, nonvertebral and hip fractures should be used preferentially over agents that only demonstrate vertebral antifracture efficacy. This is the case for alendronate, risedronate, zoledronic acid, denosumab and strontium ranelate. Finally, therapeutic decisions should be based on a balance between benefits and risks of treatment, which must be carefully considered in each particular case both by the physician and the patient. Indeed, no single agent is appropriate for all patients and, therefore, treatment decisions should be made on an individual basis, taking into account all measures of treatment effect and risk before making informed judgments about the best individual treatment option.
journal_name
Drugsjournal_title
Drugsauthors
Reginster JYdoi
10.2165/11587570-000000000-00000subject
Has Abstractpub_date
2011-01-01 00:00:00pages
65-78issue
1eissn
0012-6667issn
1179-1950pii
4journal_volume
71pub_type
杂志文章,评审相关文献
DRUGS文献大全abstract::Although vasodilator drugs are of proven worth in the management of patients with severe heart failure, a useful system of classification of vasodilator drugs has not yet been devised. The traditional system of classification based on the dominant arterial and/or venous sites of action as determined by limb plethysmog...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-198224010-00003
更新日期:1982-07-01 00:00:00
abstract::Nadroparin calcium is a low molecular weight heparin with a mean molecular weight of 4.5 kD. Compared with unfractionated heparin, nadroparin calcium has a greater ratio of anti-factor Xa/anti-factor IIa activity. Nadroparin calcium has a longer half-life and greater bioavailability than unfractionated heparin and can...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199244050-00010
更新日期:1992-11-01 00:00:00
abstract::Results from prevalence, case-control, angiographic and echocardiographic investigations incriminate elevated fibrinogen levels as a strong independent risk factor for the occurrence of initial and recurrent cardiovascular events. Average fibrinogen levels are higher in women and persons with other risk factors includ...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199700543-00006
更新日期:1997-01-01 00:00:00
abstract::The most positive results in this area have been those of the second Danish Study Group on Verapamil in Myocardial Infarction (1990) which assessed the benefit of treatment with verapamil from the second week after myocardial infarction. Verapamil produced a significant reduction in both mortality and reinfarction rat...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199100421-00005
更新日期:1991-01-01 00:00:00
abstract::Serious hepatotoxicity is uncommon with the proper therapeutic use of non-narcotic analgesics but experience with new non-steroidal anti-inflammatory drugs (NSAIDs) is limited. Drugs such as ibufenac, fenclofenac and benoxaprofen were withdrawn from the market because of hepatotoxicity, and liver damage has been repor...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-198600324-00010
更新日期:1986-01-01 00:00:00
abstract:BACKGROUND:The combination of an inhaled corticosteroid (ICS) and a long-acting bronchodilator is recommended in the treatment of patients with chronic obstructive pulmonary disease (COPD) who have frequent exacerbations. Budesonide/formoterol dry powder inhaler (DPI) has demonstrated efficacy and tolerability in patie...
journal_title:Drugs
pub_type: 杂志文章,多中心研究,随机对照试验
doi:10.2165/00003495-200868140-00004
更新日期:2008-01-01 00:00:00
abstract::In this paper the different aspects of the role played by alpha-adrenoceptors in the control of renin secretion from the juxtaglomerular apparatus and renal sodium and water reabsorption, and the effects of alpha-adrenoceptor antagonists on systemic haemodynamics, will be investigated. Animal experiments suggest that ...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-198800356-00007
更新日期:1988-01-01 00:00:00
abstract::Methotrexate has been approved for the treatment of refractory rheumatoid arthritis by several regulatory agencies, including the Food and Drug Administration. The tendency is now to prescribe it at earlier stages of the disease. Methotrexate is a well known antifolate. Its exact mechanism of action in rheumatoid arth...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199447010-00003
更新日期:1994-01-01 00:00:00
abstract::Interstitial lung disease (ILD) can be associated with all connective tissue diseases and is an important cause of morbidity and mortality. The management of connective tissue disease-interstitial lung disease (CTD-ILD) is challenging due substantial heterogeneity in disease behaviour and paucity of controlled clinica...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-019-01178-x
更新日期:2019-09-01 00:00:00
abstract::Metabolites of arachidonic acid have a broad range of physiological functions in the gastrointestinal tract, and seem to be involved in certain disturbances of gastrointestinal integrity and function. Prostaglandins inhibit gastric acid secretion, apparently via an adenylate cyclase-linked receptor, and also stimulate...
journal_title:Drugs
pub_type: 杂志文章
doi:10.2165/00003495-198700331-00007
更新日期:1987-01-01 00:00:00
abstract::Gefitinib (Iressa) is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that offers treatment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC), in particular in those who are harbouring EGFR mutations. In a large phase III trial (IPASS) in chemotherapy-naive Asian ...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/10489100-000000000-00000
更新日期:2009-11-12 00:00:00
abstract::Cefpodoxime, the active de-esterified molecule of the orally absorbable cephalosporin cefpodoxime proxetil, inhibits streptococci, Neisseria spp., and most Enterobacteriaceae, with MIC50 and/or MIC90 values of less than or equal to 2 mg/L; with regard to the latter family of bacteria, the MIC50 and/or MIC90 values of ...
journal_title:Drugs
pub_type: 杂志文章
doi:10.2165/00003495-199100423-00004
更新日期:1991-01-01 00:00:00
abstract::Numerous studies report the relationship between aspirin and other nonsteroidal anti-inflammatories (NSAIDs) and cancer incidence, in particular for colorectal cancer. This paper systematically reviews the evidence of the effect of aspirin and other NSAIDs on the primary prevention of colorectal and other gastrointest...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200262060-00006
更新日期:2002-01-01 00:00:00
abstract::Aspirin is currently the most widely prescribed treatment in the prevention of cardiovascular complications. The indications for the use of aspirin during pregnancy are, however, the subject of much controversy. Since the first evidence of the obstetric efficacy of aspirin in 1985, numerous studies have tried to deter...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-017-0823-0
更新日期:2017-11-01 00:00:00
abstract::The goal of organ transplantation is to provide durable organ function while minimizing risks such as infection and cancer. Induction therapy in renal transplantation provides improved short- and long-term graft outcomes compared with placebo. Three agents are currently available and widely used in the US; rabbit anti...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/11631300-000000000-00000
更新日期:2012-03-26 00:00:00
abstract::The discovery of immune inhibitory checkpoints has revolutionized the approach to the systemic treatment of cancer. The programmed death 1 (PD-1) inhibitory checkpoint, in particular, has played a key role in understanding how certain cancers can evade immune surveillance. Blocking the interaction between the PD-1 rec...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-015-0376-z
更新日期:2015-04-01 00:00:00
abstract::Cenobamate (XCOPRI®) is an oral, small molecule neurotherapeutic azole compound that is being developed by SK Life Science Inc. and Arvelle Therapeutics for the treatment of epilepsy. Based on results of two pivotal phase 2 trials, cenobamate was recently approved in the USA for use in the treatment of partial-onset s...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-019-01250-6
更新日期:2020-01-01 00:00:00
abstract::With its approval more than 15 years ago, subcutaneous etanercept (Enbrel(®)) was the first biological disease-modifying antirheumatic drug (bDMARD) and the first tumour necrosis factor inhibitor to be approved for use in rheumatic diseases. Etanercept remains an important cost-effective treatment option in adult pati...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-014-0258-9
更新日期:2014-08-01 00:00:00
abstract::Varicella zoster virus (VZV), a member of the herpesvirus family, is responsible for both primary (varicella, chickenpox) as well as reactivation (zoster, shingles) infections. In immunocompetent patients, the course of varicella is generally benign. For varicella zoster, post-herpetic neuralgia is the most common com...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199957020-00005
更新日期:1999-02-01 00:00:00
abstract::Avapritinib (AYVAKIT™) is a potent and selective tyrosine kinase inhibitor of platelet-derived growth factor receptor alpha (PDGFRA) and KIT activation loop mutants. It is being developed by Blueprint Medicines for the treatment of gastrointestinal stromal tumours (GIST), solid tumours and systemic mastocytosis. Avapr...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-020-01275-2
更新日期:2020-03-01 00:00:00
abstract::Lumasiran (Oxlumo™) is a subcutaneously administered small interfering RNA (siRNA) targeting the mRNA for hydroxyacid oxidase 1 gene (HAO1; encodes glycolate oxidase) and was developed by Alnylam Pharmaceuticals for the treatment of primary hyperoxaluria type 1 (PH1). By silencing the gene encoding glycolate oxidase, ...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-020-01463-0
更新日期:2021-01-06 00:00:00
abstract::Sotagliflozin (Zynquista™) is the first dual inhibitor of sodium-glucose co-transporter-1 and -2 (SGLT1 and 2). In the phase 3, inTANDEM 1-3 trials, adjunctive use of oral sotagliflozin (200 mg or 400 mg once daily) improved glycaemic control and reduced bodyweight and insulin requirements relative to placebo over 24 ...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-019-01230-w
更新日期:2019-12-01 00:00:00
abstract::Rupatadine (Rupafin, Rinialer, Rupax, Alergoliber) is a selective oral histamine H(1)-receptor antagonist that has also been shown to have platelet-activating factor (PAF) antagonist activity in vitro. It is indicated for use in seasonal allergic rhinitis (SAR), perennial allergic rhinitis (PAR) and chronic idiopathic...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200767030-00008
更新日期:2007-01-01 00:00:00
abstract::Chlamydia trachomatis infections are exceedingly prevalent, and can be associated with significant sequelae. The major infections are urethritis, cervicitis, salpingitis, and ocular infection. Chlamydial genital infections present as syndromes, where C. trachomatis is one of the causes of the syndrome. Because specifi...
journal_title:Drugs
pub_type: 杂志文章
doi:10.2165/00003495-198427050-00005
更新日期:1984-05-01 00:00:00
abstract::Vivus' proprietary oral capsule containing phentermine and extended-release (ER) topiramate has been approved in the US for the treatment of obesity. Phentermine is an appetite suppressant, while topiramate is an anti-epileptic medication. The once-daily formulation, known as Qsymia™, is designed to produce weight los...
journal_title:Drugs
pub_type: 杂志文章
doi:10.2165/11640860-000000000-00000
更新日期:2012-10-22 00:00:00
abstract::Accumulating evidence suggests the involvement of estrogen in depression. Estrogen can modulate neurotransmitter turnover, enhancing the levels of serotonin and noradrenaline (norepinephrine), and it is involved in the regulation of serotonin receptor number and function. Across the female reproductive life, fluctuati...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/11635960-000000000-00000
更新日期:2012-09-10 00:00:00
abstract::Slowing of nerve conduction, a hallmark of both experimental and human diabetic neuropathy, is improved or corrected by aldose reductase inhibitors such as sorbinil. Animal experiments suggest that a myo-inositol-related defect in nerve sodium-potassium adenosine triphosphatase (ATPase) is responsible for the acute re...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-198600322-00004
更新日期:1986-01-01 00:00:00
abstract::The development of thrombosis involves 4 main factors: the vessel wall, the formed elements of the blood, blood coagulation, and blood flow. In venous thrombosis, however, the major part in both the initiation and growth of thrombi is played by the platelets. In selecting drugs which inhibit platelet function it is he...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-197509010-00003
更新日期:1975-01-01 00:00:00
abstract::Terfenadine is a selective histamine H1-receptor antagonist which, in pharmacodynamic studies, is devoid of central nervous system depressant activity. In clinical studies terfenadine is well tolerated and at a dose of 60mg administered twice daily the drug provides effective relief of symptoms in patients with allerg...
journal_title:Drugs
pub_type: 临床试验,杂志文章,评审
doi:10.2165/00003495-199039040-00006
更新日期:1990-04-01 00:00:00
abstract::Crizotinib (Xalkori(®)) is an orally active, small molecule inhibitor of multiple receptor tyrosine kinases, including anaplastic lymphoma kinase (ALK), c-Met/hepatocyte growth factor receptor and c-ros oncogene 1. In the EU, crizotinib has been conditionally approved for the treatment of adults with previously treate...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-013-0142-z
更新日期:2013-12-01 00:00:00